A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

New England Journal of Medicine

Volumn 342, Issue 20, 2000, Pages 1484-1491

  Rascol, Olivier ^a,g   Brooks, David J ^b   Korczyn, Amos D ^c   De Deyn, Peter P ^d   Clarke, Carl E ^e   Lang, Anthony E ^f  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INCIDENCE; INDOLES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0034682308     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200005183422004     Document Type: Article

References (31)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280:337-45.
2. Calne DB, Teychenne PF, Leigh PN, Bamji AN, Greenacre JK. Treatment of parkinsonism with bromocriptine. Lancet 1974;2:1355-6.
3. Hubble JP. Novel drugs for Parkinson's disease. Med Clin North Am 1999;83:525-36.
4. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 1998;51:Suppl 2:S21-S24.
5. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment, Ann Neurol 1987;22:8-12.
6. Fahn S. Levodopa-induced neurotoxicity: does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 1997;8:376-93.
7. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989;39:336-9.
8. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 1998;50: Suppl 3:S1-S57.
9. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.
10. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-10.
11. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:1196-8.
12. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8:257-62.
13. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48: 363-8.
14. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord 1998;13:46-51.
15. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-41.
16. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-9. [Erratum, Neurology 1997;49:1484.]
17. Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. Mov Disord 1998;13:39-45.
18. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm Suppl 1995;45:231-8.
19. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998;51: 1057-61. [Erratum, Neurology 1999;52:435.]
20. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51:745-52.
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
22. Korten JJ, Keyser A, Joosten EM, Gabreels FJ. Madopar versus Sinemet: a clinical study on their effectiveness. Eur Neurol 1975;13(2):65-71.
23. Diamond SG, Markham CH, Treciokas LJ. A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease. Ann Neurol 1978;3:267-72.
24. Fahn S, Elton R, Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, eds. Recent developments in Parkinson's disease. New York: MacMillan, 1987:153-63.
25. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 2. The design and analysis of cohort studies. Lyon, France: International Agency for Research on Cancer, 1987. (IARC scientific publications no. 82.)
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
27. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 1999;53:364-70. [Erratum, Neurology 1999;53: 1162.]
28. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease: a multicemer 5 year study. Eur Neurol 1997;37(1):23-7.
29. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-5.
30. Chase TN. Levodopa therapy: consequences of nonphysiologic replacement of dopamine. Neurology 1998;50:Suppl 5:S17-S25.
31. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-10.